[The reversible procaine amide-induced lupus-erythromatosus syndrome].
D000368:Aged; D000906:Antibodies / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis / Q000302:isolation & purification; D001706:Biopsy; D003345:Corticosterone / Q000627:therapeutic use; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007678:Kidney Glomerulus / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D009504:Neutrophils; D011342:Procainamide / Q000009:adverse effects*; D013954:Thyroglobulin
D000906:Antibodies; D000974:Antibodies, Antinuclear; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013954:Thyroglobulin; D011342:Procainamide; D003345:Corticosterone
Das reversible procainamid-induzierte Lupus-erythematodes-Syndrom.